Medincell to Present Strategy at Jefferies Conference
Medincell announces the participation of Christophe Douat and Richard Malamut at the Jefferies London Global Healthcare Conference on November 18, 2025.
Presentation Details
According to the press release, Christophe Douat, CEO, and Richard Malamut, Chief Medical Officer of Medincell, will present the company at the Jefferies London Global Healthcare Conference. This event is scheduled for Tuesday, November 18, 2025, at 4:00 PM GMT (5:00 PM Paris time). The presentation can be accessed live or on replay through a link provided by the company. Individual meetings with the management and business development team can also be arranged.
Company Overview
Medincell, a biopharmaceutical company based in Montpellier, focuses on the development of long-acting injectable drugs. The company utilizes its proprietary BEPO technology to ensure controlled drug release over an extended period. The first treatment, UZEDY, aimed at treating schizophrenia, was approved by the FDA in April 2023 and is marketed in the United States by Teva. Medincell collaborates with various pharmaceutical companies to develop new treatment options.
Forward-Looking Statements
The press release reminds that certain forward-looking statements may be subject to risks and uncertainties. The company emphasizes that forecasts are based on reasonable assumptions but may vary due to uncontrollable factors. Medincell does not commit to publicly updating these statements. Readers are therefore advised not to rely solely on these anticipations for their investment decisions.
